Eli Lilly And Hims & Hers Partner To Expand Access To Zepbound And Orforglipron At Standard Self-Pay Prices
Agreement gives patients a path to FDA-approved treatments at self-pay price through the Hims & Hers platformEli Lilly and Company (NYSE:LLY) and Hims & Hers Health, Inc. (NYSE:HIMS) today announced an agreement
Eli Lilly and Hims partnered to sell weight loss medicines more easily. When companies work together to reach more patients, it shows confidence in their products and strategy.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.